Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 40 38541 04950 99059 505--
Entreprise Value (EV)1 38 28335 29150 09850 31348 74545 378
P/E ratio 17,5x20,3x15,8x12,3x14,7x15,0x
Yield ------
Capitalization / Revenue 6,02x5,22x6,00x4,87x5,29x5,09x
EV / Revenue 5,70x4,49x5,90x4,11x4,33x3,88x
EV / EBITDA 12,3x10,3x11,8x7,64x8,94x7,80x
Price to Book 4,90x3,70x4,71x3,60x2,90x2,35x
Nbr of stocks (in thousands) 108 125109 323105 544103 556--
Reference price (USD) 374375483575575575
Announcement Date 02/06/201902/06/202002/05/2021---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 6 7117 8638 49712 23111 25011 699
EBITDA1 3 1103 4204 2456 5845 4515 817
Operating profit (EBIT)1 2 5342 2103 5775 5404 5284 887
Operating Margin 37,8%28,1%42,1%45,3%40,3%41,8%
Pre-Tax Profit (EBT)1 2 5542 4293 8105 6744 5274 881
Net income1 2 4442 1163 5134 9843 9414 136
Net margin 36,4%26,9%41,3%40,8%35,0%35,4%
EPS2 21,318,530,546,839,038,4
Dividend per Share2 ------
Announcement Date 02/06/201902/06/202002/05/2021---
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 Q3 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4
Net sales1 2 2942 4232 5293 9652 8542 870
EBITDA1 1 1121 2291 3112 3621 4611 324
Operating profit (EBIT)1 1 0531 1671 1131 9061 1691 105
Operating Margin 45,9%48,2%44,0%48,1%41,0%38,5%
Pre-Tax Profit (EBT)1 9981 2251 2531 7561 2451 180
Net income1 8421 1491 1151 6511 0741 021
Net margin 36,7%47,4%44,1%41,6%37,6%35,6%
EPS2 7,3910,210,115,810,19,98
Dividend per Share ------
Announcement Date 11/05/202002/05/202105/06/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 ------
Net Cash position1 2 1015 7578919 19110 76014 127
Leverage (Debt / EBITDA) -0,68x-1,68x-0,21x-1,40x-1,97x-2,43x
Free Cash Flow1 1 8122 0002 0044 7014 6914 389
ROE (Net Profit / Equities) 32,8%28,5%33,2%36,2%24,0%22,1%
Shareholders' equity1 7 4517 42710 59513 77316 39918 683
ROA (Net Profit / Asset) 23,8%15,9%22,0%26,3%18,3%17,4%
Assets1 10 24913 27015 98418 91921 53623 765
Book Value Per Share2 76,3102102160198244
Cash Flow per Share2 19,121,222,751,343,653,3
Capex1 383430615597588602
Capex / Sales 5,71%5,46%7,23%4,88%5,22%5,15%
Announcement Date 02/06/201902/06/202002/05/2021---
1 USD in Million
2 USD
Key data
Capitalization (USD) 59 504 500 482
Net sales (USD) 8 497 100 000
Number of employees 9 447
Sales / Employee (USD) 899 450
Free-Float 82,2%
Free-Float capitalization (USD) 48 891 562 223
Avg. Exchange 20 sessions (USD) 373 915 247
Average Daily Capital Traded 0,63%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA